Skip to main content
. 2016 Jul 31;10(5):444–454. doi: 10.1177/1753465816661091

Table 4.

Immune related adverse events (%) in patients treated with nivolumab.

Study CHECKMATE 063 [Horn et al. 2015] ONO-4538-050 [Nakagawa et al. 2015] CHECKMATE 017 [Brahmer et al. 2015]
Immune related adverse events All grade Grade 3/4 Grade 3/4 Grade 3/4 All grade Grade 3/4
Skin 15.5 0 0 0 28.6 0
Gastrointestinal 11.6 0.8 1 1 5.7 0
Pulmonary 7.0 2.3 1 1 5.7 0
Endocrinopathies 6.2 0 0 0 11.4 0
Hepatitis 4.7 0.8 0 0 5.7 0
Renal injury 3.1 0 1 1 2.9 0